Perspective Therapeutics

Perspective’s in-house discovery team has developed and optimized peptide PSV359 with potential best-in-class characteristics for targeting FAP – the hot new pan-cancer target everyone is talking about. The peptide shows high uptake and retention in preclinical tumor models of sarcoma, with rapid renal clearance. Further information will be available in upcoming presentations and publications. Follow our progress on socials and the website: https://lnkd.in/ePh7Z6Zh #nuclearmedicine #radiopharma #oncology

Introducing PSV359 – a novel FAP-targeting peptide! It is a significant addition to our clinical pipeline as we continue to advance targeted #alphatherapeutics to fight #cancers. Learn more about our pipeline: https://lnkd.in/e3G62Def #nuclearmedicine #radiopharma #oncology

Save the date! May 15 – Perspective Therapeutics to provide recent business highlights and report 1Q financial results: https://lnkd.in/ewdpdeJD

Did you know - Fibroblast Activation Protein-α (FAP) is a potential game-changer in #cancer therapy? Primarily expressed on tumor stroma cells, FAP represents a promising target across multiple cancer types which might be suitable for therapeutic radiopharmaceuticals. https://lnkd.in/ePh7Z6Zh #nuclearmedicine #radiopharma #oncology

Perspective senior management will participate in several upcoming conferences in May. Check our newsroom for more details -> https://lnkd.in/eWS6WvqZ

FAP promotes #tumor cell proliferation, migration, and invasion, which ultimately leads to tumor growth. Can it be the next “big thing” for cancer therapy? https://lnkd.in/ePh7Z6Zh #nuclearmedicine #radiopharma #oncology

What is a “Pan-Cancer” Target? Pan is Greek for “all”, meaning a target that works for a range of #cancers. Novel #radiopharmaceutical imaging studies support Fibroblast Activation Protein-α (FAP) as the next promising pan-cancer target. #oncology https://lnkd.in/ePh7Z6Zh

NEWS ALERT! Our [212Pb]VMT α NET was selected by the FDA to participate in the Chemistry, Manufacturing, and Controls ("CMC") CDRP program. CDRP program is designed to facilitate alignment of CMC development of novel products under IND with expedited timeframes based upon the anticipated clinical benefits of earlier patient access. "Our priority is to expeditiously investigate whether [212Pb]VMT α NET can benefit patients beyond current standard of care in NETs, and if so, be ready to supply patients," said Thijs Spoor, CEO. Learn more at https://lnkd.in/e5wFRsN2

We're #hiring a new Manager, Regulatory Affairs in United States. Apply today or share this post with your network.

We're #hiring a new Senior Director, Biostatistician in United States. Apply today or share this post with your network.